ASH 2022 | Intensity of induction regimens and outcomes of patients with Ph+ ALL undergoing alloSCT
Marlise Luskin
• 11 Dec 2022
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, highlights a study which investigated whether the intensity of induction regimens impacted outcomes of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (alloSCT). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Research Funding; Pfizer: Honoraria; Novartis: Research Funding.
